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Edited by Gunnar von Heijne and Anders LiljasAbstract The multiprotein Mediator (Med) complex is an evo-
lutionarily conserved transcriptional regulator that plays impor-
tant roles in activation and repression of RNA polymerase II
transcription. Prior studies identiﬁed a set of more than twenty
distinct polypeptides that compose the Saccharomyces cerevisiae
Mediator. Here we discuss eﬀorts to characterize the subunit
composition and associated activities of the mammalian Med
complex.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The initiation of messenger RNA synthesis is a major site for
the regulation of gene expression. The initiation of eukaryotic
messenger RNA synthesis is an elaborate biochemical process
that is catalyzed by the 12 subunit enzyme RNA polymerase II
and requires, for simply a basal level of initiation, a minimum
of ﬁve general initiation factors designated TFIIB, TFIID,
TFIIE, TFIIF, and TFIIH, which comprise more than 20 dis-
tinct polypeptides. Regulation of transcription initiation by
RNA polymerase II is further complicated by the requirement
for a very large, multisubunit ‘‘adaptor’’ that bridges RNA
polymerase II and its myriad DNA binding regulatory proteins
and transduces both positive and negative signals that turn on
and oﬀ messenger RNA synthesis in response to the ever
changing microenvironment of the cell. This adaptor, which
is now known to be evolutionarily conserved and ubiquitouslyAbbreviations: ARC, activator-recruited cofactor; CRSP, cofactor re-
quired for Sp1 activation; Cse2, chromosome segregation 2; CTD,
carboxyl terminal domain; DRIP, vitamin D receptor-interacting pr-
otein; Med, Mediator; MudPIT, multidimensional protein identiﬁca-
tion technology; Nut, negative regulation of URS2; ORF, open
reading frame; Rgr1, resistance to glucose repression 1; SMCC, Srb-
Med-containing cofactor; Srb, suppressor of RNA polymerase B;
TRAP, thyroid hormone receptor-associated protein
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more than twenty subunits and has been named Mediator
(Med) for its role in mediating transcriptional signals from
DNA binding transcription factors bound at upstream pro-
moter elements and enhancers to RNA polymerase II and
the general initiation factors bound at the core promoter sur-
rounding the transcriptional start site.2. Saccharomyces cerevisiae Mediator
The Mediator was identiﬁed and ﬁrst puriﬁed to near homo-
geneity from S. cerevisiae by Kornberg and coworkers, by vir-
tue of its ability to promote activator-dependent transcription
by puriﬁed RNA polymerase II and the general initiation fac-
tors in vitro [1]. This brought to light, for the ﬁrst time, the
enormous complexity of the S. cerevisiae Med complex, by
demonstrating that it was composed of some 20 proteins
including the products of the Srb2, Srb4, Srb5, Srb6, and
Gal11 genes. The S. cerevisiae Srb genes were initially isolated
in a genetic screen for extragenic suppressors of an RNA poly-
merase II mutant containing a partial deletion of the heptad
repeats in the carboxyl terminal domain (CTD) of its largest
subunit [2] and found to copurify in a high molecular mass
complex that was capable of supporting activator-dependent
RNA polymerase II transcription in vitro [3,4]. The Gal11 gene
was initially isolated as gene required for transcription of
galactose-inducible genes [5].
Further characterization of the puriﬁed S. cerevisiae Med
complex by Kornberg and coworkers led to the identiﬁcation
as Med subunits of the product of the Srb7 gene [6], the prod-
ucts of the Rgr1 and Sin4 genes [7], the product of the Rox3
gene [8], the product of the Pgd1 Hrs1 gene [6], a collection
of previously uncharacterized S. cerevisiae proteins, which they
designated Med1, Med2, Med4, Med6, Med7, and Med8 [6],
the products of the Cse2, Nut1, and Nut2 genes [9], and a pre-
viously uncharacterized protein, which they designated Med11
[9]. Yeast strains carrying Rgr1 and Sin4 mutations exhibit
similar transcriptional defects. Yeast strains carrying an Rgr1
mutation failed to repress transcription of the Suc2 gene in
the presence of glucose [10]. Yeast strains carrying a Sin4
mutation are defective in repressing transcription of the Gal1
and HO endonuclease genes [11,12]. Yeast strains carrying
Rox3 mutations fail to repress transcription of the heme-regu-blished by Elsevier B.V. All rights reserved.
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netic screen for extragenic suppressors of the hyperrecombina-
tion phenotype of yeast carrying a deletion of the Hpr1 gene
[14]. Yeast strains carrying Pdg1/Hrs1 mutations were found
to be defective in activation of transcription of the Gal10 gene
[14]. The Nut1 and Nut2 genes were initially isolated in a genet-
ic screen for yeast mutants defective in transcriptional activa-
tion by the DNA binding activator Swi4 [15]. The Cse2 gene
was isolated in a genetic screen for yeast strains defective in
chromosome segregation [16].
In addition to deﬁning the subunit composition of the
S. cerevisiae Med complex, Kornberg and coworkers charac-
terization of the biochemical properties of their puriﬁed Med
preparations led to the initial identiﬁcation of many of the
known Med-associated activities [1]. They and others pro-
vided direct evidence that Med binds tightly not only to the
transcriptional activation domains of DNA binding transcrip-
tion factors [17,18], but also to RNA polymerase II to form a
‘‘holoenzyme’’ [1,4], consistent with the model that Med par-
ticipates directly in activator-dependent recruitment of poly-
merase to promoters. Although it is not yet completely
clear as to how Med interacts with RNA polymerase II, evi-
dence suggests that yeast Med can bind directly to the heptad
repeats in enzymes CTD [1], and, through analysis of elec-
tron micrographs of the holoenzyme, it appears that Med
makes multiple contacts with polymerase, with important
contacts provided by Med interactions with the Rpb3 and
Rpb11 polymerase subunits [19,20]. Perhaps not surprising
in light of Meds signiﬁcant interaction with RNA polymer-
ase II in the preinitiation complex, yeast Med exerts potent
stimulation of transcription initiation in reactions carried
out in the absence of activators [1]. Binding of Med to
RNA polymerase II was found to stimulate phosphorylation
of the CTD heptad repeats by the TFIIH-associated CTD ki-
nase [1]. Finally, S. cerevisiae Med was found to have associ-
ated histone acetyltransferase (HAT) activity likely carried
out by its Nut1 subunit [21].3. Subunit composition of the mammalian Med complex
Multiprotein mammalian Med-like complexes have been iso-
lated in several laboratories by a variety of procedures and
include the thyroid hormone receptor-associated proteins/
SRB-Med containing cofactor (TRAP/SMCC) [22–25], activa-
tor-recruited factor-large (ARC-L) [26,27], vitamin D recep-
tor-interacting proteins (DRIP) [28], positive cofactor 2
(PC2) [25], cofactor required for Sp1 activation (CRSP)
[29,27], mouse Med [30], and rat Med [31–34] complexes. Clon-
ing and analysis of the genes encoding subunits of these com-
plexes revealed that many bear striking sequence similarity to
yeast Med subunits. These include obvious orthologs of S.
cerevisiae Med subunits Srb7, Med6, Med7, Nut2, Srb10,
and Srb11. In addition, bioinformatic and biochemical analy-
ses identiﬁed among the subunits of mammalian Med-like
complexes potential orthologs of all S. cerevisiaeMed subunits
except for Med2, Pgd1/Hrs1, and Nut1 [32–36]. Interestingly,
although the mammalian MED1 protein is predicted to be
an ortholog of S. cerevisiaeMed subunit Med1, it also contains
LXXLL motifs, which mediate ligand-dependent interaction
of mammalian Med with class I and class II nuclear receptors
not found in yeast. The MED1 protein was initially identiﬁedas TRIP2 (thyroid receptor interacting protein 2) and PBP
(PPAR binding protein) in yeast two-hybrid screens, by its
ability to interact in a ligand-dependent manner with the thy-
roid hormone and PPAR receptors, respectively [37,38]. In
light of evidence that the MED1 protein is not required for
structural integrity of the mammalian Med complex and thus
far appears to mediate activation of RNA polymerase II tran-
scription only by nuclear receptors, the MED1 protein may
play a specialized role in transcriptional regulation in mamma-
lian cells [39].
Despite signiﬁcant similarities in the subunit compositions
of mammalian Med complexes isolated in diﬀerent laborato-
ries, apparent diﬀerences were notable (Fig. 1). The MED30
and MED31 proteins were initially identiﬁed only in the
TRAP/SMCC complex [23,40]; the MED25 protein only in
the ARC, DRIP, and CRSP complexes [26–29]; the
MED26 protein only in the CRSP and DRIP complexes
[27–29]; the MED8 protein only in the ARC and rat Med
complexes [26]; the MED18 protein only in the mouse and
rat Med complexes [30,32]; and the MED9, MED11,
MED19, MED22, MED28, and MED29 only in rat Med
[32–34].4. Proteomic analysis of the mammalian Med complex
Although the precise explanation for the apparent diﬀer-
ences in subunit compositions of the various mammalian
Med complexes characterized in diﬀerent laboratories is cur-
rently not known, recent proteomic analyses suggests that
most of the Med-associated proteins identiﬁed in diﬀerent lab-
oratories are bona ﬁde subunits of the complex [41]. In these
experiments, multidimensional protein identiﬁcation technol-
ogy (MudPIT) was used to characterize the subunit composi-
tion of a variety of mammalian Med complexes puriﬁed by
anti-FLAG agarose immunoaﬃnity chromatography from
cultured cells stably expressing a FLAG-tagged Med subunit.
MudPIT is an exquisitely sensitive ‘‘shotgun proteomics’’ ap-
proach for identifying the constituents of complex mixtures
of proteins [42,43]. In MudPIT, all of the proteins in a mixture
are digested without prior separation into peptides, which are
then separated by two-dimensional cation exchange and re-
verse phase HPLC and analyzed by in-line tandem mass
spectrometry.
MudPIT analyses of multiprotein complexes puriﬁed from
HeLa cell lines stably expressing either FLAG-MED10,
FLAG-MED9, FLAG-MED29, FLAG-MED19, FLAG-
MED28, FLAG-MED26 [41], or FLAG-MED8 (unpublished
data) identiﬁed 37 proteins present in all seven preparations
but not in the control. Among those proteins were 29 of 30
proteins previously identiﬁed as components of various mam-
malian Med complexes characterized in diﬀerent laboratories
(Fig. 1). The 30th protein, cyclin C, was identiﬁed by MudPIT
in all but one preparation, but its presence was conﬁrmed in all
by Western blotting. Taken together, these results argue that
all of the proteins previously identiﬁed as components of the
various mammalian Med-like complexes are indeed bona ﬁde
Med subunits.
The only additional proteins present in all seven Med prep-
arations but not in the control were subunits of RNA polymer-
ase II, a MED13-related protein, MED13L, encoded by the
KIAA1025 open reading frame (ORF), and a cyclin-dependent
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Fig. 1. Comparison of mammalian Med subunits identiﬁed in diﬀerent laboratories and by MudPIT. Mammalian Med subunits identiﬁed in the rat
Med, TRAP/SMCC, ARC, DRIP, mouse Med (mMED), PC2, CRSP, and MudPIT analyses are indicated in blue. Proteins not detected are
indicated in yellow. The asterisk in cyclin C MudPIT data from F:Med9 and F:Med26 expressing HeLa cells indicates that cyclin C was not detected
in these Med preparations by MudPIT, but was detected by Western blotting.
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lated to the Med subunit Cdk8. Mutations in MED13L are
associated with a congenital heart defect called transposition
of the great arteries (TGA), suggesting that MED13 and
MED13L have non-redundant functions and may regulate
the expression of distinct populations of genes. MudPIT anal-
yses of multiprotein complexes puriﬁed from HeLa cell lines
stably expressing either FLAG-Cdk8 or FLAG-Cdk11 has re-
vealed the existence of distinct forms of Med that contain
either Cdk8 or Cdk11 (unpublished data). Finally, a
MED12-related protein, MED12L, encoded by the TRAL-
PUSH ORF (Accession No. NP_443728) was identiﬁed by
MudPIT analysis of a mammalian Med complex isolated from
HEK 293 cells but not from HeLa cells (unpublished data),
suggesting that MED12L may be a component of a cell-type
or tissue-speciﬁc form of Med.5. Conclusions and future prospects
The deﬁnition of a set of consensus mammalian Med sub-
units provides a solid foundation for future studies systemati-
cally dissecting the functions of individual subunits in
reconstitution of the mammalian Med and its associated activ-
ities. Among the major questions to be addressed is how the
Med promotes communication between DNA binding regula-
tory proteins and RNA polymerase II and the general initia-
tion factors. It is now well-established that the Med from
yeast, Drosophila, and yeast is capable of binding directly to
the transcriptional activation domains of many DNA binding
regulatory proteins, which appear to function in part to recruit
Med to genes [44–46]. A variety of evidences accumulated to
date supports the intriguing model that diﬀerent DNA binding
regulatory proteins may target Med to genes through direct
J.W. Conaway et al. / FEBS Letters 579 (2005) 904–908 907interactions with diﬀerent Med subunits. Although the details
of interactions between mammalian Med subunits and tran-
scriptional activation domains are still emerging, documented
examples include the interactions of MED1, MED23, and
MED25 with nuclear receptors, VP16, and E1A and Elk1,
respectively [46–49]. Thus, future studies illuminating the
mechanisms underlying targeting of Med by the myriad
DNA binding regulatory proteins active in a given cell will
be critical for an in-depth understanding of Med function
and gene transcription.
In addition, in light of evidence that Med is likely to be pres-
ent in cells in multiple, functionally distinct forms, a major aim
of future studies will be to identify the repertoire of Med
assemblies and subassemblies and to elucidate their functions.
Studies to date have identiﬁed distinct Med forms including
and lacking the Cdk8/cyclin C/MED12/MED13 module and
have obtained tantalizing evidence that Med including the
Cdk8 module may lack associated RNA polymerase II and
can function as a transcriptional repressor under some condi-
tions ([27,47,50,51] and our unpublished results). With the
identiﬁcation of Med forms containing either Cdk8 or Cdk11
and combinations of MED12/MED13 and the related
MED12L/MED13L proteins, the number of predicted Med
forms that may perform non-redundant functions in cells has
increased further. Thus, future studies cataloguing the number
of distinct Med forms and establishing the mechanisms of their
interconversions and their likely gene-speciﬁc functions will be
essential.Acknowledgement: This work was supported in part by National Insti-
tutes of Health Grant R37 GM041628.References
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